Lymphocytes from certain portion of patients cannot be adequately expanded to generate sufficient quality CAR-T cells. With this hurdle in the mind, Gracell is developing our own solution that would provide much better cost economics, mass production per lot, and followed by one-shot release, not specific to each individual patient. TruUCAR will be purely for off-the-shelf use.
TruUCAR technology is based on lymphocytes obtained from healthy donors and modified with gene editing to avoid GvHD as well as rejection. Genetic modification is also executed to protect from host versus graft (HvG) reaction, and to enhance TruUCAR T cell persistence and proliferation. Lead program is a treatment for T cell malignancies, and it is to enroll patients soon.